Our Parkinson's Place: Opicapone As Levodopa Adjunct Cuts Motor Fluctuations in PD

I HAVE PARKINSON'S DISEASES AND THOUGHT IT WOULD BE NICE TO HAVE A PLACE WHERE THE CONTENTS OF UPDATED NEWS IS FOUND IN ONE PLACE. THAT IS WHY I BEGAN THIS BLOG.

I COPY NEWS ARTICLES PERTAINING TO RESEARCH, NEWS AND INFORMATION FOR PARKINSON'S DISEASE, DEMENTIA, THE BRAIN, DEPRESSION AND PARKINSON'S WITH DYSTONIA. I ALSO POST ABOUT FUNDRAISING FOR PARKINSON'S DISEASE AND EVENTS. I TRY TO BE UP-TO-DATE AS POSSIBLE.

I AM NOT RESPONSIBLE FOR IT'S CONTENTS. I AM JUST A COPIER OF INFORMATION SEARCHED ON THE COMPUTER. PLEASE UNDERSTAND THE COPIES ARE JUST THAT, COPIES AND AT TIMES, I AM UNABLE TO ENLARGE THE WORDING OR KEEP IT UNIFORMED AS I WISH. IT IS IMPORTANT TO UNDERSTAND I AM A PERSON WITH PARKINSON'S DISEASE. I HAVE NO MEDICAL EDUCATION,

I JUST WANT TO SHARE WITH YOU WHAT I READ ON THE INTERNET. IT IS UP TO YOU TO DECIDE WHETHER TO READ IT AND TALK IT OVER WITH YOUR DOCTOR. I AM JUST THE COPIER OF DOCUMENTS FROM THE COMPUTER. I DO NOT HAVE PROOF OF FACT OR FICTION OF THE ARTICLE. I ALSO TRY TO PLACE A LINK AT THE BOTTOM OF EACH ARTICLE TO SHOW WHERE I RECEIVED THE INFORMATION SO THAT YOU MAY WANT TO VISIT THEIR SITE.

THIS IS FOR YOU TO READ AND TO ALWAYS KEEP AN OPEN MIND.

PLEASE DISCUSS THIS WITH YOUR DOCTOR, SHOULD YOU HAVE ANY QUESTIONS, OR CONCERNS. NEVER DO ANYTHING WITHOUT TALKING TO YOUR DOCTOR FIRST..

I DO NOT MAKE ANY MONEY FROM THIS WEBSITE. I VOLUNTEER MY TIME TO HELP ALL OF US TO BE INFORMED.

I WILL NOT ACCEPT ANY ADVERTISEMENT OR HEALING POWERS, HEALING FROM HERBS AND ETC. UNLESS IT HAS GONE THROUGH TRIALS AND APPROVED BY FDA. IT WILL GO INTO SPAM.

THIS IS A FREE SITE FOR ALL WITH NO ADVERTISEMENTS

THANK YOU FOR VISITING! TOGETHER WE CAN MAKE A DIFFERENCE!

Wednesday, December 28, 2016

Opicapone As Levodopa Adjunct Cuts Motor Fluctuations in PD

December 27, 2016

In Parkinson's disease, 50-mg/day opicapone linked to significant reduction in mean daily off-time

For patients with Parkinson's disease receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, according to a study published online Dec. 27 in JAMA Neurology.

TUESDAY, Dec. 27, 2016 (HealthDay News) -- For patients with Parkinson's disease (PD) receiving levodopa therapy and experiencing end-of-dose motor fluctuations, treatment with 50-mg/day opicapone is associated with a reduction in mean daily off-time, according to a study published online Dec. 27 in JAMA Neurology.

Andrew J. Lees, M.D.,from University College London, and colleagues enrolled 427 patients with PD receiving levodopa therapy who experienced signs of end-of-dose deterioration into a phase 3 trial. Participants were randomized to a 14- to 15-week placebo-controlled trial (129 received 25-mg/day opicapone, 154 received 50-mg/day opicapone, and 144 received placebo). Of the 376 patients who completed the double-blind phase, 286 completed a one-year open-label phase in which all patients received opicapone.

The researchers found that the least squares mean change in off-time was −64.5 minutes for the placebo group, and −101.7 and −118.8 minutes for the 25- and 50-mg/day opicapone groups, respectively. For the 50-mg/day opicapone group, the adjusted treatment difference versus placebo was significant (−54.3 minutes; P = 0.008); the difference was not significant for the 25-mg group (−37.2 minutes; P = 0.11). Throughout the open-label phase, the off-time reduction was sustained (−126.3 minutes at one-year end point).

"Treatment with a 50-mg once-daily dose of opicapone was associated with a significant reduction in mean daily off-time in levodopa-treated patients with PD and motor fluctuations, and this effect is maintained for at least one year," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including BIAL, which manufactures opicapone and funded the study.

http://www.doctorslounge.com/index.php/news/pb/68867